SAM #75N98026Q00970

NIH Solicitation for Synthesis of Five Research Compounds for Ewing Sarcoma Studies

The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, is soliciting proposals for the synthesis of research compounds to support Ewing sarcoma studies. - Government Buyer: - National Institutes of Health (NIH), Office of the Director, Office of Logistics and Multiple Acquisition Operations - Contact: Jaddua Johnston - Products/Services Requested: - Synthesis of five specific chemical compounds (5 grams each) - ABCL-0482: N-Methyl-N-(3-(((2-((2-oxoindolin-5-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)methyl)pyridin-2-yl)methanesulfonamide - A1-133143: N,N-Diethyl-3-(5-phenyl-1,2,4-oxadiazol-3-yl)pyrrolidine-1-carboxamide - A1-133142: N-(3-Acetyl-2-methylbenzofuran-5-yl)-N-((4-methoxyphenyl)sulfonyl)isonicotinamide - ABCL-0485: 3,4,5-Trimethoxy-N-(4-((9-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl)methoxy)phenyl)benzamide - A1-133147: N-Cycloheptyl-5-methyl-4-oxo-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide - Each compound must be synthesized under non-GMP conditions, with ≥95% purity and accompanied by a Certificate of Analysis - Delivery of all compounds to NIH/NCATS in Rockville, MD - Unique/Notable Requirements: - Biweekly progress updates and participation in teleconferences - Notification of any issues or delays - Strict purity and documentation standards (≥95% purity, Certificate of Analysis) - All compounds are for research use only (not for clinical or GMP applications) - No specific OEMs or commercial vendors are named; the opportunity is open to qualified chemical synthesis providers - The period of performance is up to 12 weeks, with individual compound lead times ranging from 8 to 12 weeks

Description

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes only solicitation; proposals are being requested, and a separate written solicitation will not be issued.(ii) The solicitation number is 75N98026Q00970. This solicitation is issued as a competitive combined synopsis/solicitation for commercial products or commercial services. The Government intends to award a contract or purchase order resulting from this solicitation using full and open competition.This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold (if applicable).The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, seeks to award a (Firm-Fixed-Price) to the offeror responsible whose proposal represents the best value to the Government.(iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular effective August 7, 2026(iv) The associated NAICS code is 541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) and the small business size standard is 1000 employees.This requirement is unrestricted.

View original listing